Human pluripotent stem cell-derived products: Advances towards robust, scalable and cost-effective manufacturing strategies

The ability to develop cost-effective, scalable and robust bioprocesses for human pluripotent stem cells (hPSCs) will be key to their commercial success as cell therapies and tools for use in drug screening and disease modelling studies. This review outlines key process economic drivers for hPSCs an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, Michael J, Farid, Suzanne S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: WILEY-VCH Verlag 2015
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674985/
https://www.ncbi.nlm.nih.gov/pubmed/25524780
http://dx.doi.org/10.1002/biot.201400348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674985/
https://www.ncbi.nlm.nih.gov/pubmed/25524780
http://dx.doi.org/10.1002/biot.201400348

Ejemplares similares